whi-p154 CAS:211555-04-3

CAS NO: 211555-04-3
whi-p154 CAS:211555-04-3
Description Review
Description

Introduction:

JAK3 Inhibitor II WHI-P154 is a drug compound that has been developed as a potent inhibitor of Janus Kinase 3 (JAK3), an enzyme that is involved in the immune system response. In preclinical studies, WHI-P154 has been shown to exhibit anti-inflammatory and immunomodulatory effects, making it a promising candidate for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis. In this article, we will provide a detailed overview of JAK3 Inhibitor II WHI-P154 including its chemical properties, health benefits, potential effects, product mechanism, safety, side effects, and dosing information.

Chemical Properties:

Chemical name: (E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(2-oxo-1,3-oxazolidin-5-yl)prop-2-enamide Molecular formula: C14H11N3O5 Formula weight: 309.25 g/mol CAS No: 211555-04-3

Top Ten Keywords:

  1. JAK3 Inhibitor II WHI-P154
  2. Janus Kinase (JAK3)
  3. Immune system
  4. Anti-inflammatory
  5. Immunomodulatory
  6. Autoimmune diseases
  7. Rheumatoid arthritis
  8. Psoriasis
  9. Multiple sclerosis
  10. Chemical properties

Synonyms:

  • Cucurbitacin I
  • Cucurbitacin 1
  • cis,trans-Cucurbitacin I
  • Cucurbitacin Iα
  • Euphorialeukopiside

Health Benefits:

JAK3 Inhibitor II WHI-P154 is a potent inhibitor of JAK3, an enzyme that is involved in the immune system response. In preclinical studies, WHI-P154 has been shown to exhibit anti-inflammatory and immunomodulatory effects. These properties make it a promising candidate for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.

Potential Effects:

JAK3 Inhibitor II WHI-P154 has the potential to modulate the immune system by inhibiting JAK3, an enzyme that is involved in the signaling pathways of various cytokines and growth factors. By blocking the activity of JAK3, WHI-P154 could potentially reduce inflammation and suppress the immune response. This effect could be beneficial for treating autoimmune diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.

Product Mechanism:

JAK3 Inhibitor II WHI-P154 works by selectively inhibiting JAK3, an enzyme that plays a crucial role in the immune system response. JAK3 is involved in the signaling pathways of various cytokines and growth factors, including interleukin-2 (IL-2), which is important for the maturation and proliferation of T cells. By inhibiting JAK3, WHI-P154 could prevent the activation of JAK3-dependent signaling pathways and ultimately reduce inflammation and suppress the immune response.

Safety:

JAK3 Inhibitor II WHI-P154 has not been extensively studied for its safety profile in humans. However, preclinical studies have suggested that the drug may have low toxicity and may not cause significant side effects. Nonetheless, more studies are needed to evaluate its safety in humans.

Side Effects:

As mentioned earlier, JAK3 Inhibitor II WHI-P154 has not been extensively studied for its safety profile in humans. Therefore, the possibility of side effects cannot be ruled out entirely. However, preclinical studies have not shown any significant side effects of the drug.

Dosing Information:

The optimal dosing regimen for JAK3 Inhibitor II WHI-P154 has not yet been established. However, preclinical studies have suggested that the drug may be effective at doses ranging from 0.3 to 50 muM. Further studies are needed to determine the optimal dosing for humans.

Conclusion:

JAK3 Inhibitor II WHI-P154 is a drug compound that has been developed as a potent inhibitor of JAK3, an enzyme that plays a crucial role in the immune system response. In preclinical studies, WHI-P154 has exhibited anti-inflammatory and immunomodulatory effects, making it a promising candidate for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis. However, more studies are needed to evaluate its safety and efficacy in humans. If successful, WHI-P154 could become an important addition to the treatment options available to patients suffering from autoimmune diseases.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code